Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
CONNECTA Therapeutics logo — Promoting neuroplasticity modulation.

CONNECTA Therapeutics

Promoting neuroplasticity modulation.

Founded 2019 Spain Spain 7 employees Seed Total: $4.40M Biotechnology, Health Care

General Information

Company Name CONNECTA Therapeutics
Founded Year 2019
Location Spain Spain
Employees 7
Industries Biotechnology, Health Care
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with CONNECTA Therapeutics. To contact CONNECTA Therapeutics, visit connectatherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does CONNECTA Therapeutics compare?

A PDF of CONNECTA Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting CONNECTA Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About CONNECTA Therapeutics

Connecta Therapeutics is a biotechnology startup based in Spain with a slogan of "Promoting neuroplasticity modulation." Founded in 2019, the company focuses on developing new treatments for CNS unmet medical needs. Their initial focus is on the clinical development of a new "first-in-class" molecule for the treatment of fragile X syndrome (FXS), the most common cause of hereditary intellectual disability with no current therapeutic interventions available. The discovered molecule, after evaluating more than 30 molecular and cellular targets, has shown promising results in in vitro tests and in vivo animal models, proving to be an excellent neuroplasticity modulator with a great extension profile for other neurodevelopmental disorders such as Rett syndrome, Down syndrome, and autism spectrum disorders. The latest funding round on 12 February 2024 amounted to €2.70M and was supported by a consortium of investors including Inveready, CDTI, Ministry of Science and Innovation of Spain, NextGenerationEU, Prous Institute for Biomedical Research, ENISA, and NEOTEC demonstrating the market's confidence in Connecta Therapeutics. As the company continues to progress in its endeavors, the potential impact of its novel approach to addressing neurological disorders makes Connecta Therapeutics a compelling entity to watch in the biotechnology and healthcare sectors.

Business keywords: neuroplasticity modulation, biotechnology company, CNS treatments, fragile X syndrome, intellectual disability, therapeutic interventions, molecular targets, neurodevelopmental disorders, Rett syndrome, Down syndrome, autism spectrum disorders, drug development, in vitro tests, in vivo animal models, neurology

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round €2.70M 8
Inveready Ministry of Science and Innovation of Spain NextGenerationEU
Inveready, Ministry of Science and Innovation of Spain +6
12 Feb 2024
Seed Round €1.70M 2
Inveready
Inveready, Centre for the Development of Industrial Technology (CDTI)
27 Sep 2020

CONNECTA Therapeutics Alternatives & Competitors

View All Alternatives
CONNECTA Therapeutics vs
Prilenia
Prilenia United States

Dedicated to developing new treatments for neurodegenerative diseases and neurodevelopmental disorde...

Series B
57 employees
Biotechnology, Health Care
CONNECTA Therapeutics vs
Myrobalan Therapeutics
Myrobalan Therapeutics United States

Myro’s mission is to develop first-in-class and best-in-class small molecule drugs for CNS disorders...

Grant
27 employees
Biotechnology, Health Care
CONNECTA Therapeutics vs
AnnJi Pharmaceutical Co., Ltd.
AnnJi Pharmaceutical Co., Ltd. Taiwan

Taiwan's Leading New Drug Developer In Dermatology & Neurology

18 employees
Biotechnology, Health Care
View all alternatives

FAQ About CONNECTA Therapeutics

Promoting neuroplasticity modulation.
CONNECTA Therapeutics was founded in 2019.
CONNECTA Therapeutics is headquartered in Spain.
CONNECTA Therapeutics operates in Biotechnology and Health Care. Its work centres on neuroplasticity modulation, biotechnology company, CNS treatments and fragile X syndrome.
CONNECTA Therapeutics has approximately 7 employees.
CONNECTA Therapeutics has completed 2 funding rounds, raising a total of $4.40M. The latest funding stage is Seed.
Top alternatives and competitors to CONNECTA Therapeutics include Prilenia, Myrobalan Therapeutics, AnnJi Pharmaceutical Co., Ltd., Neuraly Inc., Elixirgen Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CONNECTA Therapeutics and Prilenia are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CONNECTA Therapeutics, https://bouncewatch.com/company/connecta-therapeutics, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout